FDA panel to meet and vote on whether a diabetes drug reduces the risk of cardiovascular death

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

An FDA panel will meet on June 28 and vote on whether empagliflozin (Jardiance) reduces the risk of cardiovascular death in high-risk patients, Reuters reports. When the FDA approved empagliflozin in 2014 to treat patients with type 2 diabetes, the agency asked the drug’s manufacturers (Eli Lilly & Co. and Boehringer Ingelheim) to conduct a trial to prove the medication did not increase the risk of heart problems.

The companies published the results in January and showed that the drug decreased the risk of death from MI, the risk of death from any cause and the combined risk of cardiac death, non-fatal MIs and non-fatal strokes.

Read the story below: